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Abstract
Background: Total thyroidectomy is the treatment of choice in the majority of thyroid malignancies, preventing the 
risk of reoperative surgery due to recurrences. In order to assess the usefulness of such an approach, expression levels 
of inflammatory and proliferative markers were evaluated immunohistochemically in non-lesional adjacent thyroid 
tissues from a group of patients who underwent total thyroidectomy for different thyroid diseases.
Methods: Nineteen consecutive patients treated by total thyroidectomy for different thyroid diseases entered the 
study. IL-6Rb gp130 component of the IL-6 cytokine family members receptor complexes, STAT3 cytokine signalling 
transduction and transcription activation factor, p53 as tumour suppressor and CK19 cytokeratin as proliferation 
marker were analyzed in non-lesional thyroid tissues.
Results: Gp 130 expression was detected in all tissue samples with a scattered distribution while STAT3 and p53 
positivity was observed in 17 out of 19 patients with a prevailing cytoplasmic localization. Cytokeratin 19 positivity was 
found in patients with papillary carcinoma, in one case of follicular adenoma, 3 multinodular goiters and one Basedow 
disease.
Conclusion: Based on the results of this preliminary study, it may be concluded that the presence of a persisting 
cytokine-mediated activation associated with cytoplasmic localization of p53 is frequently observed in different thyroid 
diseases. Such a process seems to occur in the thyroid gland as a whole. Moreover, STAT3 activation as well as mutant 
p53 are risk factors for the development of neoplastic diseases. Total thyroidectomy may be supported as an adequate 
therapeutic approach for all the patients in whom overexpression of cytokine-dependent markers is detected.
Introduction
Thyroiditis includes a complex spectrum of pathologies
in which inflammatory and autoimmune processes may
be detected in coexistence with benign and malignant
proliferative lesions [1].
Therefore total thyroidectomy is increasingly being
considered as the treatment of choice,
preventing the risk of reoperation required for possible
recurrences. The present study reports the expression of
inflammatory and proliferative biological markers in
non-lesional healthy thyroid tissue obtained from
patients undergoing total thyroidectomy for various thy-
roid diseases. Our study tried to rationalise the usefulness
of total thyroidectomy in the management of thyroiditis
hypothesizing that in a chronic thyroid disease the asso-
ciated inflammatory and/or autoimmune phenomenona
may involve the whole gland and exert a modulatory
effect with respect to carcinogenesis [2]. The IL-6 pro-
inflammatory cytokine IL-6Rb gp130 component medi-
ates high affinity binding of IL-6 to the IL-6Ra subunit,
and constitutes the functional component of other IL-6
cytokine family members receptor complexes, such as
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Oncostatin M, Leukemia Inhibitory Factor and IL-11,
through a wide array of inflammatory and immune
responses [3]. Cytokine-dependent signalling activation
involves the STAT proteins family as an important path-
way to modulate different cell functions, where STAT3
plays a central role in transmitting signals from the mem-
brane to the nucleus [4]. The tumour suppressor p53
senses multiplicity of cellular stresses, gets activated by
post-translational mechanisms to induce cell-cycle arrest,
senescence, or apoptosis and is a STAT3 functional regu-
lator [5]. Constitutively active STAT3 is frequently
expressed in a variety of human cancers and transformed
cell lines associated to a mutated inactive p53 [6,7]. Thus,
in this study, together with gp130, we analysed by immu-
nohistochemistry the expression and intracellular local-
ization of STAT3 and p53, to verify whether we could
detect a cytoplasmic localization of the oncosuppressor
protein indicative of its functional inactivation [8]. CK 19
cytokeratin which is expressed on epithelial tissue both in
benign and malignant processes [9] was used as marker
of epithelial tissue.
Patients and Methods
Nineteen consecutive female patients who underwent
total thyroidectomy for various thyroid diseases were
investigated. Diseases included multinodular goiter (n =
10), follicular adenoma (n = 2), papillary carcinoma (n =
6) and Basedow disease [1]. Two patients with papillary
carcinomas presented with concomitant Hashimoto dis-
e a s e  o r  t h y r o t o x i c  g o i t e r  ( T a b l e  1 ) .  M e a n  a g e  o f  t h e
patients was 44 years (range 19-59) and disease duration
ranged from 6 months to 25 years. Anti-thyroid antibod-
ies were negative in all the patients.
Biopsy tissues used for immunohistochemical analyses
were obtained from normal tissue adjacent to diseased
areas. Samples were immediately frozen in liquid Nitro-
gen and stored at -80°C. On the day of analysis, tissue
samples were gradually set to the temperature of -30°C
for cryostat procedure. Seven sections were cut from
each sample. The immunoperoxidase method was
applied with Vector reagents utilizing the following pri-
mary antibodies: a)  the anti-p53 polyclonal antibody
CM-1 (Novocastra Laboratories Ltd) dilution 1:1000, b)
the anti-STAT3 polyclonal antibody C-20 sc-482 clone
(Santa Cruz Biotechnology) dilution 1:1000, c) the anti-
CK19 monoclonal antibody b170 (Novocastra Laborato-
ries Ltd) dilution 1:100, d) the anti-gp130 polyclonal anti-
body H-255 (Santa Cruz Biotechnology) dilution 1:250.
The staining pattern was evaluated in epithelial cells both
in terms of percentage of stained cells and staining inten-
sity. In terms of percentage of stained cells, samples were
classified as diffuse, zonal, focal and negative when the %
of positive cells was >50%, between 10-50%, <10% and
0%, respectively. In terms of staining intensity, samples
were subdivided into three categories: 1 + (low), 2 +
(intermediate) and 3 + (high).
Results
The results of immunohistochemical analyses are shown
in Table 1. Except for case number 8 (multinodular goi-
ter) that was negative for both STAT3 and p53 expres-
sion, and case number 14 (papillary carcinoma) which
was negative for STAT3, a diffuse pattern with an inter-
mediate intensity in both nuclear and/or cytoplasmic
localizations was observed in all the samples analyzed.
An exclusive cytoplasmic localization of STAT3 was seen
in 7 cases while a nuclear/cytoplasmic staining was
detected in 10 cases. As for p53, three cases displayed an
exclusive nuclear staining, 8 cases showed an exclusive
cytoplasmic localization, 7 cases showed a nuclear/cyto-
plasmic positivity [Figure 1] and one case displayed no
staining. gp130 staining was negative in two cases (3 and
8) while a zonal or focal membrane and cytoplasmic
staining distribution of intermediate intensity (2+) was
observed in most of the cases [Figure 2]. Cases 7, 15 and
19 showed an intense (3+) staining. Cytokeratin 19
(CK19) could not be determined in case 3, while 7 sam-
ples were negative, 8 showed a focal and 3 a zonal cyto-
plasmic distribution of intermediate intensity (2+).
Discussion
The present work addresses the usefulness of total thyroi-
dectomy based on biomarkers expression in apparently
normal thyroid tissue in patients with various thyroid dis-
eases. We evaluated gp130 expression as a constituent of
receptor complexes common to a number of cytokines
implicated in inflammatory and immune responses. Of
these, Interleukin-6 (IL-6), a most important pleiotropic
cytokine, plays a central role in immune regulation,
inflammation, hematopoiesis, and oncogenesis. In our
series, gp 130 expression was detected in all patients with
a scattered distribution represented by groups of cells of
variable size, confirming the involvement of cytokines
signalling through the gp130 subunit. An earlier immu-
nohistochemical study on the expression pattern of the
IL-6 family members and their receptor subunits in nor-
mal prostate, benign prostatic hyperplasia, and prostatic
carcinoma has suggested a role for this cytokine in both
paracrine and autocrine regulation of proliferative pro-
cesses [10]. In another study on oesophageal carcinoma it
has been suggested that IL-6 may contribute to cancer
progression in an autocrine or paracrine manner acting
as an antiapoptotic factor [6]. As for STAT3 and p53
expression, both markers were found to be overexpressed
in 17 out of the 19 patients studied with a prevailing cyto-
plasmic localization (in 5 cases we observed an exclu-Ardito et al. Journal of Experimental & Clinical Cancer Research 2010, 29:77
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sively cytoplasmic pattern). Although our series was
relatively small and no robust statistical analysis could be
performed, the data obtained did not show any signifi-
cant differential pattern of distribution amongst tissues
obtained from multinodular goiter, adenoma, autoim-
mune disease or papillary carcinoma. As previously men-
tioned, the transcription factor STAT3 is most important
for the signal transduction of interleukin-6 and related
cytokines. Upon stimulation cytoplasmic STAT3 is phos-
phorylated and translocates to the nucleus. When consti-
tutively activated, STAT3 plays an important role in
tumorigenesis, as shown in human breast cancer [5].
Table 1: Results of the immunohistochemical staining on non-lesional tissue from 19 totally thyroidectomized patients.
Patient n. Disease STAT3 P53 CK19 Gp130
1 Multinodular goiter N/C N/C neg F
2P a p i l l a r y  c a n c e r C N / C F F
3 Follicular adenoma N/C N ND ND
4 Multinodular goiter C C neg Z
5 Multinodular goiter C C neg Z
6P a p i l l a r y  c a n c e r N / C C Z Z
7 Multinodular goiter N/C N/C neg Z
8 Multinodular goiter neg neg neg ND
9 Multinodular goiter C C neg F
10 Papillary cancer & Thyrotoxic goiter N/C C F F
11 Basedow disease C C F F
12 Papillary cancer N/C N/C Z Z
13 Multinodular goiter N/C N neg Z
14 Papillary c. neg C Z Z
15 Multinodular goiter N/C N/C F Z
16 Follicular adenoma C N F Z
17 Multinodular goiter N/C N/C F Z
18 Multinodular goiter N/C N/C F F
19 Papillary cancer & Hashimoto C C F Z
C = cytoplasmic; N = nuclear; F = focal; Z = zonal; ND = not determined; neg. = negativeArdito et al. Journal of Experimental & Clinical Cancer Research 2010, 29:77
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Wild-type p53 contributes to negatively regulate STAT3
phosphorylation. Thus, a mutant p53, as is the case for
cytoplasmic p53, is also associated with constitutive
STAT3 activation [7]. In the present study we did not
investigate the STAT3 phosphorylation and the p53
mutational status as our aim was to evaluate their subcel-
lular localization in apparently normal thyroid tissue and
to verify whether differences exist amongst different thy-
roid diseases. The results are suggestive of an ongoing
modulation mechanism, where an increased p53 expres-
sion level is observed with a main cytoplasmic localiza-
tion, going along with an almost equivalent localization
pattern for STAT3.
Conclusion
On the basis of the present data, it may be concluded that
activation of STA3 signalling is a frequent event in thy-
roid diseases, being observed in normal thyroid tissue
adjacent to different types of thyroid diseases. Such a pro-
cess seems to involve the whole thyroid gland. Since a
constitutively active STAT3, associated to cytoplasmic
accumulation of p53, has been reported to represent a
risk factor for tumor development [11], total thyroidec-
tomy may be supported as an adequate therapeutic
choice in cases where such alterations are detected.
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